WO2013056508A1 - 一种调节血脂的药物组合物及其制备工艺 - Google Patents
一种调节血脂的药物组合物及其制备工艺 Download PDFInfo
- Publication number
- WO2013056508A1 WO2013056508A1 PCT/CN2012/001386 CN2012001386W WO2013056508A1 WO 2013056508 A1 WO2013056508 A1 WO 2013056508A1 CN 2012001386 W CN2012001386 W CN 2012001386W WO 2013056508 A1 WO2013056508 A1 WO 2013056508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- regulating blood
- parts
- blood lipids
- sea buckthorn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the invention relates to a pharmaceutical composition for regulating blood lipids and a preparation process thereof.
- hyperlipidemia is also an important risk factor for promoting hypertension, impaired glucose tolerance, and diabetes.
- Hyperlipidemia can also lead to fatty liver, cirrhosis, cholelithiasis, pancreatitis, fundus hemorrhage, blindness, peripheral vascular disease, lameness, Hyperuricemia, so we must attach great importance to the harm of high blood lipids, active prevention and treatment.
- the technical problem solved by the invention is to provide a drug combination which is rigorous in combination, scientific in science, effective in effect, can exert a greater effect on drugs, has short curative effect, quick effect, easy consolidation, safe use and no side effects to regulate blood lipids. And its preparation process.
- a pharmaceutical composition for regulating blood lipids which is special in that the composition of the drug is The raw material composition of the active ingredient and its weight ratio are:
- the above-mentioned raw material composition constituting the active ingredient of the medicinal composition and its weight ratio are: 55 parts of Gynostemma pentaphyllum and 230 parts of sea buckthorn oil.
- the above pharmaceutical composition is in the form of a soft capsule or granule or a tablet or a pill or an oral solution.
- Gynostemma saponin is passed through a 200 mesh sieve, and the weight is weighed according to the formula amount; then the seabuckthorn seed oil is weighed according to the formula amount.
- the capsule shell glue is made of 80-240 parts by weight of gelatin, and the semi-finished product is filled with soft capsules;
- Gynostemma saponin is passed through a 200 mesh sieve, and the weight is weighed according to the formula amount; then the seabuckthorn seed oil is weighed according to the formula amount;
- the capsule shell glue is made of 80-240 parts by weight of gelatin, and the pellets are formed by the dropping method.
- the dosage form of the above pharmaceutical composition is the process of preparing the oral liquid as follows: Take the formula amount of Gynostemma pentaphyllum and sea buckthorn oil, mix evenly, pack, package, and inspect the storage.
- the preparation process of the above pharmaceutical composition is the following steps of preparing the capsule: taking the formula amount of Gynostemma pentaphyllum and sea buckthorn oil, forming microcapsules by physical chemical method, solidifying, separating, drying, performing capsule filling, packaging, inspection Storage.
- the preparation process of the above pharmaceutical composition is the following steps of preparing the granules: taking the formula amount of Gynostemma pentaphyllum and sea buckthorn oil, forming microcapsules by physical chemical method, solidifying, separating, drying, filling and packing the particles, packaging , check the storage.
- the dosage form of the above pharmaceutical composition is a process for preparing a tablet as follows: taking a predetermined amount of Gynostemma pentaphyllum and sea buckthorn oil, forming a microcapsule by physical chemistry, adding the microcapsule to a suitable dispersing agent and an appropriate amount of stearic acid Magnesium is compressed, packaged, and inspected.
- the invention consists of Gynostemma pentaphyllum, sea buckthorn oil and gelatin.
- Gynostemma saponins are used for anti-inflammatory and detoxification, and modernized to cure obesity, hepatitis, hyperlipidemia, arteriosclerosis, etc., found in modern pharmacological research: significant decline of Gynostemma pentaphyllum Lipid is related to the inhibition of fatty acid production by fat cells and the synthesis of neutral fat.
- Gynostemma pentaphyllum has the effect of lowering cholesterol and triglycerides and increasing high-density protein.
- sea buckthorn oil is the most medicinal part of sea buckthorn
- vitamin E is The main vitamin component of seabuckthorn
- modern pharmacology research can extend the role of sea buckthorn oil to improve immunity, anti-tumor, anti-myocardial ischemia and hypoxia, lowering blood fat, anticoagulation, anti-aging, etc.
- Seabuckthorn oil has significant hypolipidemic The effect is that the seabuckthorn oil is similar to vitamin E from the subcellular level.
- the vascular smooth muscle cells damaged by seabuckthorn oil and high fat serum have protective effects and can significantly increase the activation of superoxide dismutase, which can reduce the protection of high fat serum on cell membrane. Promoting the healthy growth of cells, the present invention uses seabuckthorn oil as a carrier to mix Gynostemma saponins in seabuckthorn oil, and the two are compatible with each other to regulate blood lipids.
- the invention adopts advanced pharmaceutical equipment, scientifically extracts and refines the active ingredients in the medicine, separates impurities, and prepares a dosage form which is convenient for oral carrying, thereby realizing the effect of regulating blood lipids, thereby improving people's health level. .
- the invention is based on modern clinical experience, with reference to historical medical literature and data research, combined with long-term clinical experience practice and preliminary clinical research cases to make the following statements on the medicinal properties in the formula:
- Gynostemma pentaphyllum a dry whole grass of Gynostemmapentaphyllum (Thunb.) Makino of the genus Gynostemma, a perennial climbing herb, whose medicinal parts are rhizomes or whole grasses, sweet, bitter, cold, beneficial to qi
- Animal experiments and clinical trials have confirmed that Gynostemma pentaphyllum has the effect of preventing and treating hyperlipidemia, hyperviscosity and atherosclerosis.
- the lipid-lowering effect is related to inhibiting the production of free fatty acids and synthesizing neutral fat by fat cells.
- seabuckthorn seed oil contains a variety of medicinal active ingredients, and is rich in a large number of volatile oil plant protein, 18 kinds of amino acids and human essential fat-soluble vitamins and other nutrients, to improve human immune function, prevention and It can treat cancer and improve the body's ability to resist radiation.
- seabuckthorn seed oil can also stimulate the secretion of gastric juice. It has excellent therapeutic effects on indigestion, gastritis, gastric ulcer, duodenal ulcer, enteritis and chronic constipation.
- gelatin is a mixture of water-soluble protein, collagen in skin, ligament and tendon is partially hydrolyzed by acid or alkali or boiled in water, colorless or yellowish transparent chip or coarse powder, at 35 ⁇ 40'C Swelling in water to form a gel (water is 5 to 10 times its own weight), is a nutrient incomplete protein, lacks certain essential amino acids, especially tryptophan, widely used in foods and adhesives, photoreceptors, filters, etc.
- the invention consists of Gynostemma pentaphyllum, sea buckthorn oil and gelatin.
- the Gynostemma pentaphyllum is used for anti-inflammatory and detoxification, and has been extended to treat obesity, hepatitis, hyperlipidemia and arteriosclerosis in modern times. It is found in the modern pharmacological research: the significant drop of Gynostemma pentaphyllum Lipid is related to the inhibition of fatty acid production by fat cells and the synthesis of neutral fat. Gynostemma pentaphyllum has the effect of lowering cholesterol and triglycerides and increasing high-density protein.
- Seabuckthorn has activating blood circulation, digestive stagnation, and coughing
- the role of seabuckthorn oil is the most medicinal part of seabuckthorn, and vitamin E is the main vitamin component of seabuckthorn.
- Modern pharmacology research can extend the role of seabuckthorn oil to improve immunity, anti-tumor, anti-myocardial ischemia and hypoxia, Reduce blood fat, anticoagulant, anti-aging, etc.
- Seabuckthorn oil has obvious hypolipidemic effect. It is confirmed from the subcellular level that seabuckthorn oil is similar to vitamin E. However, vascular smooth muscle cells damaged by seabuckthorn oil and high fat serum have protective effect and can be significantly increased.
- Activation of hyperoxide dismutase can reduce the protection of high-fat serum on cell membrane
- the healthy growth of the cells so the sea buckthorn oil as the carrier, the Gynostemma saponin is mixed in the sea buckthorn oil, the two are compatible with each other to regulate blood lipids.
- the invention adopts advanced pharmaceutical equipment, scientifically extracts and refines the active ingredients in the medicine, separates impurities, and prepares a dosage form which is convenient for oral carrying, thereby realizing the effect of regulating blood lipids, thereby improving people's health level. .
- the serum triglyceride levels of the rats in each dose group were lower than those in the high-fat control group, and the differences were highly significant (P ⁇ 0.01).
- HDL-C 2.5 serum high density lipoprotein cholesterol
- HDL-C Serum high-density lipoprotein cholesterol
- the serum high-density lipoprotein cholesterol in the rats in each dose group was higher than that in the high-fat control group.
- the difference between the doses and the high doses was highly significant. There was no significant difference between the middle and low dose groups.
- Serum total cholesterol was determined as a positive result.
- Serum triglyceride was determined as a positive result.
- Serum high-density lipoprotein cholesterol was determined as a positive result.
- the triglyceride test value was 2.67 mmol/L, and the salt-limited fat-restricted sugar-free diet was applied. After one month, the product was reduced to 1.87 mmol/L.
- the cholesterol test value is 9.5 mmol/L, and the salt-restricted fat-restricted diet is administered. After taking the product for three months, the cholesterol test value is 5. 4 mra 0 l/L.
- Example 1 The pharmaceutical composition of the present invention is composed of the following raw materials in parts by weight: 32 parts of saponin, 147 parts of sea buckthorn oil.
- the preparation method of the soft capsule of the present invention is as follows: 1), after the raw materials are qualified according to the standard, the 100,000-level purification workshop is sent; 2) Gynostemma saponin is passed through a 200 mesh sieve, and the weight is weighed according to the formula amount; then the seabuckthorn seed oil is weighed according to the formula amount;
- Example 2 The pharmaceutical composition of the present invention is composed of the following raw materials in parts by weight: Gynostemma 55 parts, and sea buckthorn oil 230 parts.
- Gynostemma saponin is passed through a 200 mesh sieve, and the weight is weighed according to the formula amount; then the seabuckthorn seed oil is weighed according to the formula amount;
- Example 3 The pharmaceutical composition of the present invention is composed of the following raw materials in parts by weight: 98 parts of saponin, 443 parts of sea buckthorn oil.
- Gynostemma pentaphyllum and sea buckthorn oil is prepared by using physical and chemical methods to form microcapsules, which are solidified, separated, dried, and filled, packaged, and inspected.
- Example 4 The pharmaceutical composition of the present invention is composed of the following raw materials in parts by weight: 70 parts of Gynostemma pentaphyllum, 320 parts of sea buckthorn oil. Take the prescribed amount of Gynostemma pentaphyllum and sea buckthorn oil, make microcapsules by physical and chemical methods, add the microcapsules to a suitable dispersing agent and appropriate amount of magnesium stearate, compress them, pack and pack, and inspect the storage.
- Example 5 The pharmaceutical composition of the present invention is composed of the following raw materials in parts by weight: 56 parts of saponin, 270 parts of sea buckthorn oil.
- the process step of the preparation method of the present invention for the preparation process of the oral liquid is as follows:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012325600A AU2012325600B2 (en) | 2011-10-19 | 2012-10-15 | Pharmaceutical composition regulating blood fat and preparation process thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110317791.7 | 2011-10-19 | ||
CN2011103177917A CN102335222B (zh) | 2011-10-19 | 2011-10-19 | 一种调节血脂的药物组合物及其制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013056508A1 true WO2013056508A1 (zh) | 2013-04-25 |
Family
ID=45511323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/001386 WO2013056508A1 (zh) | 2011-10-19 | 2012-10-15 | 一种调节血脂的药物组合物及其制备工艺 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN102335222B (zh) |
AU (1) | AU2012325600B2 (zh) |
WO (1) | WO2013056508A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547261A (zh) * | 2014-12-08 | 2015-04-29 | 陈正梅 | 一种治疗高血脂的药物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102335222B (zh) * | 2011-10-19 | 2013-05-08 | 清华德人西安幸福制药有限公司 | 一种调节血脂的药物组合物及其制备工艺 |
CN111329906A (zh) * | 2020-04-03 | 2020-06-26 | 丛艳东 | 一种预防和治疗心脑血管疾病的中药 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1857473A (zh) * | 2006-03-17 | 2006-11-08 | 崔彬 | 绞股蓝皂苷组合物制剂及制备方法 |
CN102335222A (zh) * | 2011-10-19 | 2012-02-01 | 清华德人西安幸福制药有限公司 | 一种调节血脂的药物组合物及其制备工艺 |
CN102440378A (zh) * | 2010-10-09 | 2012-05-09 | 李茸清 | 一种降血脂的保健品 |
-
2011
- 2011-10-19 CN CN2011103177917A patent/CN102335222B/zh active Active
-
2012
- 2012-10-15 AU AU2012325600A patent/AU2012325600B2/en active Active
- 2012-10-15 WO PCT/CN2012/001386 patent/WO2013056508A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1857473A (zh) * | 2006-03-17 | 2006-11-08 | 崔彬 | 绞股蓝皂苷组合物制剂及制备方法 |
CN102440378A (zh) * | 2010-10-09 | 2012-05-09 | 李茸清 | 一种降血脂的保健品 |
CN102335222A (zh) * | 2011-10-19 | 2012-02-01 | 清华德人西安幸福制药有限公司 | 一种调节血脂的药物组合物及其制备工艺 |
Non-Patent Citations (2)
Title |
---|
WANG, HAIYONG: "Progress on Blood Lipid-regulating Medicine", FOREIGN MEDICAL SCIENCES SECTION ON PHARMACY, vol. 31, no. 3, June 2004 (2004-06-01), pages 160 - 166 * |
ZHONG, XUNLONG ET AL.: "Progress on Blood Lipid-regulating Active Ingredients from Traditional Chinese Medicine", FOOD AND DRUG, vol. 12, no. 11, 2010, pages 449 - 451 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547261A (zh) * | 2014-12-08 | 2015-04-29 | 陈正梅 | 一种治疗高血脂的药物 |
Also Published As
Publication number | Publication date |
---|---|
AU2012325600A1 (en) | 2014-06-12 |
CN102335222A (zh) | 2012-02-01 |
CN102335222B (zh) | 2013-05-08 |
AU2012325600B2 (en) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7069490B2 (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び/又は刺激におけるその使用 | |
CN104274509B (zh) | 含有虫草和杜仲雄花的健康品组合物及其制备方法和应用 | |
CN1840166A (zh) | 温胆汤现代中药口服制剂及其生产方法 | |
CN102258680B (zh) | 一种缓解体力疲劳的中药组合物及其制备方法和应用 | |
CN102847159A (zh) | 一种葡萄糖新陈代谢增强剂 | |
WO2013056508A1 (zh) | 一种调节血脂的药物组合物及其制备工艺 | |
CN104306554B (zh) | 一种治疗胃溃疡的食品、保健品或药物组合物 | |
RU2351354C1 (ru) | Средство для лечения и профилактики заболеваний щитовидной железы | |
CN103142916B (zh) | 一种预防和治疗老年性痴呆病的药物 | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
CN110772564A (zh) | 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂 | |
Bikash et al. | Formulating anti-diabetic nutraceutical tablets based on edible plants from Tripura, India | |
CN105101817B (zh) | 可食用组合物及其制备方法和包含该组合物的食品 | |
US20180169071A1 (en) | Nutritional supplement composition | |
CN107536016B (zh) | 一种保护心脏和促进肝脏健康的营养食品 | |
CN103181945B (zh) | 丝瓜子的用途 | |
RU2452507C1 (ru) | Фитотранквилизатор | |
CN102225082B (zh) | 一种防治糖尿病及其并发症的药物和其制备方法 | |
CN102000250A (zh) | 一种乌鸡保健药物及其制备方法和应用 | |
CN105998098A (zh) | 一种制备治疗糖尿病肾病的中药组合物的方法 | |
WO2019218537A1 (zh) | 一种壳聚糖组合物及其制备方法 | |
CN102327304A (zh) | 一种防治慢性高原病的药物及其制备方法 | |
CN102836315A (zh) | 一种预防调理转归肿瘤的中药组合物及其制备方法 | |
Mishra et al. | Development And Evaluation Of Anti Diabetic Activity In Polyherbal Tablets Of Local Herbs | |
KR102659899B1 (ko) | 밀크씨슬추출물 및 홍경천 추출물을 포함하는 건강기능 식품 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12840885 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012325600 Country of ref document: AU Date of ref document: 20121015 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12840885 Country of ref document: EP Kind code of ref document: A1 |